Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Market Voices
Companies
Elena Nikulina
Elena Nikulina

Camp4 Therapeutics Corp advances regRNA therapy for SYNGAP1-related disorder after Nasdaq feature

Camp4 Therapeutics Corp advances regRNA therapy for SYNGAP1-related disorder after Nasdaq feature
Camp4 advances SYNGAP1 therapy

Camp4 Therapeutics Corp has been featured by Nasdaq following SYNGAP1Awareness Day, spotlighting its commitment to developing a regRNA-targeting therapy for SYNGAP1-related disorder.

The company is working to address this rare haploinsufficient disease by advancing novel therapeutic approaches that could potentially offer solutions for patients with SYNGAP1-related conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Crypto test drive: How automakers are exploring digital assets
  • By Anastasiia Chabaniuk
  • 19 hours ago
Crypto test drive: How automakers are exploring digital assets
Editors' Picks
Lindsey Graham death: U.S. senator’s crypto legacy
  • By Mikhail Vnuchkov
  • Yesterday
Lindsey Graham death: U.S. senator’s crypto legacy
Editors' Picks
Tether under pressure: USDT in Europe, audit questions, and the fight for trust
  • By Pavlo Kot
  • 12.07.2026
Tether under pressure: USDT in Europe, audit questions, and the fight for trust
Editors' Picks
All Editors' Top Picks

Latest CAMP4 News

Camp4 Therapeutics Corp advances industry and policy dialogue on orphan drug accessibility
  • By Andrey Mastykin
  • 26.06.2026
Camp4 Therapeutics Corp advances industry and policy dialogue on orphan drug accessibility
Companies
#CAMP4
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy
  • By Elena Nikulina
  • 21.05.2026
Camp4 Therapeutics Corp CEO unveils gene expression strategy with regRNA for rare disease therapy
Companies
#CAMP4
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston
  • By Ivan Andriyenko
  • 14.05.2026
Camp4 Therapeutics Corp unveils new preclinical data on SYNGAP1 seizure model in Boston
Companies
#CAMP4
All CAMP4 News
  • Anastasiia Chabaniuk
  • 19 hours ago
Crypto test drive: How automakers are exploring digital assets
  • Mikhail Vnuchkov
  • Yesterday
Lindsey Graham death: U.S. senator’s crypto legacy
  • Pavlo Kot
  • 12.07.2026
Tether under pressure: USDT in Europe, audit questions, and the fight for trust
  • Pavlo Kot
  • 11.07.2026
Lean Ethereum: Why Buterin wants to rebuild the network
  • Mikhail Vnuchkov
  • 10.07.2026
SK Hynix debuts on Nasdaq: Largest U.S. offering by foreign company
  • Yaroslav Dmytrenko
  • 46 min ago
Despite negativity, Bitcoin saw buying today, Brian Armstrong notes
  • Artem Shendetskii
  • 1 hour ago
AI ripple effects now impacting financial sector, Spiros Margaris notes
  • Andrey Mastykin
  • 1 hour ago
KOSPI up 5.4 percent with SK Hynix and SK Square surging, Jonah Lupton notes
  • Hanna Syniavska
  • 2 hours ago
Circle, Arc and USDC see growing adoption in Buenos Aires, Jeremy Allaire states
  • Ivan Andriyenko
  • 2 hours ago
U.S. inflation comes in cooler than expected, Amit Kukreja notes
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Eugene Komchuk
  • 13 hours ago
ECB selects 36 participants for digital euro pilot
ECB selects 36 participants for digital euro pilot
  • Olga Shendetskaya
  • 15 hours ago
IBM shares drop after earnings warning
IBM shares drop after earnings warning
  • Olga Shendetskaya
  • 17 hours ago
U.S. stock futures show mixed moves as oil shock puts CPI in focus
U.S. stock futures show mixed moves as oil shock puts CPI in focus
  • Hanna Syniavska
  • 18 hours ago
China trade surplus fuels new concerns in Europe
China trade surplus fuels new concerns in Europe
  • Andrey Mastykin
  • 19 hours ago
Nvidia tightens Asia AI chip sales under U.S. pressure
Nvidia tightens Asia AI chip sales under U.S. pressure
Live News
  • Anton Kharitonov
  • Now
Apple holds near record highs as AI optimism offsets technical resistance
  • Mykhailo Ihnatenko
  • Now
Moderna braces for earnings and FDA catalyst
  • Mykhailo Ihnatenko
  • Now
IBM shares tumble after weak preliminary Q2 results
  • Mykhailo Ihnatenko
  • Now
Tesla stock in focus as CPI and earnings season begin
  • Anton Kharitonov
  • Now
Bitcoin stabilizes as geopolitical risks offset improving institutional demand
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR